Form 4: Gilead Director Exercises Options, Sells Shares

Gilead Sciences Director Jeffrey Bluestone exercised 5,000 stock options and simultaneously sold the acquired shares for a profit on November 28, 2025.

Summary

• Jeffrey Bluestone, a Director at Gilead Sciences, Inc., executed a pre-planned transaction under a Rule 10b5-1(c) plan.
• On November 28, 2025, Bluestone exercised 5,000 non-qualified stock options at an exercise price of $64.92 per share.
• Immediately following the exercise, he sold all 5,000 shares of common stock acquired from the option exercise at a price of $125.08 per share.
• The options had vested immediately upon their grant date of May 8, 2024, and had an expiration date of May 8, 2034.
• After these transactions, Bluestone directly holds 8,920 shares of common stock and 7,648 non-qualified stock options.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale under a pre-planned program, indicating a director monetizing vested options. While it's a sale, the pre-planned nature and significant profit margin are neutral to slightly positive, as it reflects past stock appreciation.

Positives

• Director Jeffrey Bluestone realized a significant profit from exercising stock options and selling the shares.
• The sale price of $125.08 per share is substantially higher than the exercise price of $64.92 per share, indicating a gain of $60.16 per share.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting it was pre-scheduled and not based on immediate insider information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, as it reduces the director's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the director's sale as a signal, though the pre-planned nature mitigates concerns. The director still retains a significant number of shares and options.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned transaction by a director exercising vested stock options and selling the acquired shares. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally not indicative of new material information about the company's future performance. The director still retains a substantial equity interest. Therefore, this specific filing alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate for existing investors.

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Jeffrey Bluestone, Director, Equity Transaction, Rule 10b5-1